C.H. Robinson faces $604M jury verdict, plans appeal; Q3 revenue up 29.5% to $5.36B

Filed October 30, 2026 · Period ending September 30, 2026 · Compared to 10-Q Oct 31, 2025 · ~1 min read

Key Changes

• high

  Jury verdict in Lipe v. Lupus Superior could expose company to $604M damages plus $107M interest; company plans appeal and has $155M insurance coverage per occurrence.

  Legal Proceedings verify on EDGAR →
• high

  Agreed to acquire RXO, Inc. in stock-and-cash deal valued at ~$30.25/share; financing includes $4.5B bridge facility; expected close in H1 2027.

  MD&A: RXO Acquisition verify on EDGAR →
• high

  Restructuring charges rose to $16.1M in Q3 and $43.8M YTD; total expected cost range raised to $75M–$100M through early 2028.

  Notes: Restructuring verify on EDGAR →